The aberrant activation of RTKs, particularly by RET fusion and mutation, is implicated in numerous cancers, spanning non-small-cell lung cancer (NSCLC) to breast cancer (Bhujbal et al., 2021). This evidence concerns the gene RET and breast carcinoma.